"As the opioid epidemic continues to ravage our nation, we are privileged to partner with GeneAlign on an actionable solution to help curb the proliferation of opioid misuse, abuse and addiction that often begins through exposure to these medications in the postsurgical setting," said Dave Stack, chairman and chief executive officer of Pacira Pharmaceuticals. "This joint undertaking to revolutionize the concept of personalized medicine for our hospital patients truly embodies the Pacira corporate commitment to improve patient care."A recent article in the Journal of the American Medical Association highlighted that for opioid-naive patients, many surgical procedures are associated with an increased risk of chronic opioid use in the postsurgical period; 1 perhaps more startling, a recent national survey revealed that one in 10 patients admit they've become addicted to or dependent on opioids after being exposed to these powerful medications following an operation. 2 About Pacira Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com. About GeneAlign GeneAlign is a therapeutic management company that integrates advanced molecular diagnostics and toxicology testing with expert-guided therapeutic recommendations from licensed medical professionals to provide precision medicine solutions for perioperative medicine. GeneAlign's pharmacogenetic technologists provide clinically relevant genetic lab testing services on 19 genes associated with the metabolism, response and drug interactions for hundreds of the most commonly-prescribed medications including opioids, NSAIDS and opioid antagonists. GeneAlign's Medical Directors and PharmDs collaborate with the treating providers to provide the most appropriate and safe perioperative pain management. Substance abuse experts assist in the immediate post-operative period as part of the integrated team.
Forward Looking StatementsAny statements in this press release about our future expectations, plans, outlook and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications; the outcome of the U.S. Department of Justice inquiry; our plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical studies in support of an existing or potential DepoFoam-based product; our plans to continue to manufacture and provide support services for our commercial partners who have licensed DepoCyt(e); our commercialization and marketing capabilities; our and Patheon UK Limited's ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the "Risk Factors" of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
- Sun EC, Darnall B, Baker LC, Mackey S. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298.
- Wakefield Research on behalf of Pacira Pharmaceuticals. Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known. 2016.
Company Contact:Pacira Pharmaceuticals, Inc.Susan Mesco, (973) firstname.lastname@example.orgMedia Contact:Coyne Public RelationsAlyssa Schneider, (973) email@example.com